While previous reports showed
ADP-induced platelet reactivity to be an independent predictor of
bleeding after PCI in stable patients, this has never been investigated in patients with
cardiogenic shock. The association of
bleeding events with respect to
ADP-induced platelet aggregation was investigated in patients undergoing primary PCI for acute
myocardial infarction complicated by
cardiogenic shock and with available on-treatment
ADP-induced platelet aggregation measurements. Out of 233 patients, 74 suffered from a severe BARC3 or higher bleed.
ADP-induced platelet aggregation was significantly lower in patients with BARC≥3 bleedings (p < .001). Multivariate analysis identified on-treatment
ADP-induced platelet aggregation as an independent risk factor for
bleeding (HR = 0.968 per AU). An optimal cutoff value of <12 AU for
ADP-induced platelet aggregation to predict BARC≥3 bleedings was identified via ROC analysis. Moreover, the use of VA-ECMO (HR 1.972) or coaxial left ventricular pump (HR 2.593), first
lactate (HR 1.093 per mmol/l) and thrombocyte count (HR 0.994 per G/l) were independent predictors of BARC≥3 bleedings. In conclusion, lower on-treatment
ADP-induced platelet aggregation was independently associated with severe
bleeding events in patients with AMI-CS. The value of platelet function testing for
bleeding risk prediction and guidance of anti-thrombotic treatment in
cardiogenic shock warrants further investigation.